Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine

Lignende værker

• TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group
  af: Jørgensen, Charlotte Levin Tykjær, et al.
  Udgivet: (2014)
• The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine
  af: Stovgaard, Elisabeth S, et al.
  Udgivet: (2021)
• Aberrations of ERBB2 and TOP2A genes in breast cancer
  af: Nielsen, Kirsten Vang, et al.
  Udgivet: (2009)
• Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene
  af: Iben Kümler, et al.
  Udgivet: (2019-06-01)
• Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene
  af: Kümler, Iben, et al.
  Udgivet: (2019)